Associate Scientific Director
Brian is a clinical neuropsychologist and an associate scientific director in the global clinical science neuroscience therapeutic area unit at Takeda. He supports the use of quantitative approaches for decision-making in programs targeting cognitive impairment across a range of psychiatric, neurologic and rare pediatric CNS diseases. Brian is also a member of the neuroscience digital medicine steering committee where he is involved in the evaluation of digital technologies that assess cognition, as well as other aspects of behavior, for neuroscience TAU studies.
Prior to joining Takeda, Brian was in the Pfizer Neuroscience & Pain Research Unit for 2 years. He was directly involved in designing and successfully completing early signal of efficacy studies in Alzheimer’s Disease and adjunctive treatment of cognitive impairment associated with schizophrenia.
Prior to joining Pfizer, he was in Cogstate for 6 years providing consultation to various pharmaceutical companies and academic institutions on cognitive testing in clinical trials across a broad range of therapeutic areas (e.g., neurosciences, oncology) and populations (e.g., adult, geriatric, pediatric). He developed cognitive batteries for use in pediatric and cancer populations that have been included in a number of pharmaceutical sponsored trials, ranging from phase 2 through phase 4.
Brian specializes in neuropsychology and completed his PhD at the University of Connecticut with an internship in clinical neuropsychology at the Ann Arbor VA Healthcare System/University of Michigan Medical School, and a postdoctoral residency in clinical neuropsychology at the University of Iowa Hospitals and Clinics, Department of Neurology. Clinically, he has performed neuropsychological assessments on patients with a broad range of neurological and psychiatric disorders.
He has served as a consultant on a wide range of cognitive disorders in adult and pediatric patients (Brain Health Registry, Children’s Oncology Group, the Network of Pediatric MS Centers of Excellence, Radiation Therapy Oncology Group), and to governmental institutions such as the National Cancer Institute. His work has resulted in the validation of computerized cognitive tests appropriate for use in a number of different pediatric populations, including cancer and multiple sclerosis, as well as in adults with various types of cancer. He has publications in the areas of pediatrics, depression, Parkinson’s disease, Alzheimer’s disease, oncology, voice acoustics, and experimental medicine methods for cognition.